Theseus Pharmaceuticals, Inc.
NASDAQ:THRX
4.065 (USD) • At close February 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.023 | 0.159 | 0.155 | 0.152 | 0.149 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.023 | -0.159 | -0.155 | -0.152 | -0.149 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.519 | 12.919 | 12.401 | 10.383 | 11.423 | 7.344 | 6.548 | 5.022 | 4.996 | 4.485 | 3.825 | 2.488 | 1.275 |
| General & Administrative Expenses
| 4.884 | 4.668 | 4.654 | 5.096 | 4.525 | 4.736 | 4.031 | 3.637 | 2.378 | 2.329 | 0.664 | 0.4 | 0.154 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.884 | 4.668 | 4.654 | 5.096 | 4.525 | 4.736 | 4.031 | 3.637 | 2.378 | 2.329 | 0.664 | 0.4 | 0.154 |
| Other Expenses
| 2.899 | 2.782 | 2.469 | 1.762 | 1.203 | 0.431 | 0.082 | 0.003 | 0.002 | 0.007 | 0.016 | -0.002 | 0 |
| Operating Expenses
| 16.403 | 17.587 | 17.055 | 15.479 | 15.948 | 12.08 | 10.579 | 8.659 | 7.374 | 6.814 | 4.489 | 2.888 | 1.429 |
| Operating Income
| -16.403 | -17.587 | -17.055 | -15.479 | -15.948 | -12.08 | -10.579 | -8.659 | -7.374 | -6.814 | -4.489 | -2.888 | -1.429 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.899 | 2.782 | 2.469 | 1.762 | 1.203 | 0.431 | 0.082 | 0.003 | 0.002 | 0.007 | 0.016 | -0.002 | 0 |
| Income Before Tax
| -13.504 | -14.805 | -14.586 | -13.717 | -14.745 | -11.649 | -10.497 | -8.656 | -7.372 | -6.807 | -4.473 | -2.89 | -1.429 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.022 | 0 | -2.469 | 1.716 | -1.203 | -0.431 | -0.082 | -0.003 | -0.002 | -0.007 | -0.016 | 0.002 | 0 |
| Net Income
| -13.504 | -14.805 | -12.117 | -15.433 | -13.542 | -11.218 | -10.415 | -8.656 | -7.372 | -6.807 | -4.473 | -2.89 | -1.429 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.31 | -0.34 | -0.29 | -0.4 | -0.35 | -0.29 | -0.27 | -0.24 | -0.21 | -0.19 | -0.18 | -0.11 | -0.056 |
| EPS Diluted
| -0.31 | -0.34 | -0.29 | -0.4 | -0.35 | -0.29 | -0.27 | -0.24 | -0.21 | -0.19 | -0.18 | -0.11 | -0.056 |
| EBITDA
| -16.403 | -17.566 | -17.055 | -13.747 | -15.93 | -12.069 | -10.578 | -8.658 | -7.374 | -6.814 | -4.488 | -2.888 | -1.428 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |